0.01Open0.01Pre Close0 Volume4 Open Interest144.00Strike Price0.00Turnover605.11%IV15.44%PremiumJul 12, 2024Expiry Date0.00Intrinsic Value100Multiplier-1DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type-0.0031Delta0.0009Gamma17028.00Leverage Ratio-1.0956Theta0.0000Rho-52.45Eff Leverage0.0002Vega
AbbVie Stock Discussion
EPKINLY (Epcoritamab) Now Approved for Patients w/ Follicular Lymphoma (FL)
» Positive results in Ph1/2 EPCORE® NHL-1 study for R/R FL
» Offers off-the-shelf T-cell therapy
» First-of-its-kind antibody for both R/R FL & DLBCL after prior treatments (2+ lines)
One of the U.S.’s largest energy corporations, Chevron Corporation (NYSE:CVX) specializes in oil, gas and renewable fuels. The company has upstream and downstream operations focused on the oil and gas industry. Oil companies are an interesting pick since the best ones are known for paying dividends, even in bad times.
Chevron has a 37-year history of increasing dividends and has consistently paid them since ...
$Merck & Co(MRK.US)$ $Bristol-Myers Squibb(BMY.US)$ $Johnson & Johnson(JNJ.US)$ $Pfizer(PFE.US)$ $Novo-Nordisk A/S(NVO.US)$ $AbbVie(ABBV.US)$
$AbbVie(ABBV.US)$ +189%
$Bristol-Myers Squibb(BMY.US)$ +175%
$Johnson & Johnson(JNJ.US)$ +95%
$AstraZeneca(AZN.US)$ +78%
$NVM +45%
$Merck & Co(MRK.US)$ +37%
$ROCHE HOLDING AG(RHHBY.US)$ +27%
$Pfizer(PFE.US)$ +13%
$GlaxoSmithKline(GSK.US)$ +13%
----- $SPDR S&P 500 ETF(SPY.US)$ +12% -----
$Sanofi(SNY.US)$ +3%
Source: Arjun Murthy on the HR app!
Recently, there have been signs that World War 3 is coming (*1, *2, *3). Given the current status in the Middle East, Eastern Europe, and the Asia-Pacific, investing has become a difficult task.
In light of this hypothetical situation , I have chosen to invest from April 2024 to July 2024 using a three-pronged strategy.
Approach One: Buy the winners
Who are the winners? During wars, companies that are in the defense, oil, ...
Revenue from both companies GLP-1 drugs totaled $33.6 bil last yr, an impressive number that almost certainly will grow this yr,
But let's put that $285 bil incr in mkt value into perspective,
$AbbVie(ABBV.US)$ has a $315 bil MCap, not much bigger than the combined Q1 incr in mkt value for LLY & NVO,
ABBV had $54 bil in revenue in 2023, compared ...
$MRTX
Acquired By: Bristol-Myers Squibb $Bristol-Myers Squibb(BMY.US)$
Date: Jan. 23, 2024
Price: $4.8B
$AbbVie(ABBV.US)$ $GlaxoSmithKline(GSK.US)$
No comment yet